PL2144909T3 - [2,6]-Naftyrydyny użyteczne jako inhibitory kinaz białkowych - Google Patents
[2,6]-Naftyrydyny użyteczne jako inhibitory kinaz białkowychInfo
- Publication number
- PL2144909T3 PL2144909T3 PL08735845T PL08735845T PL2144909T3 PL 2144909 T3 PL2144909 T3 PL 2144909T3 PL 08735845 T PL08735845 T PL 08735845T PL 08735845 T PL08735845 T PL 08735845T PL 2144909 T3 PL2144909 T3 PL 2144909T3
- Authority
- PL
- Poland
- Prior art keywords
- protein kinase
- kinase inhibitors
- inhibitors
- naphthyridines
- useful
- Prior art date
Links
- SSNMISUJOQAFRR-UHFFFAOYSA-N 2,6-naphthyridine Chemical class N1=CC=C2C=NC=CC2=C1 SSNMISUJOQAFRR-UHFFFAOYSA-N 0.000 title 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 3
- 102000003964 Histone deacetylase Human genes 0.000 abstract 2
- 108090000353 Histone deacetylase Proteins 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 101100383153 Caenorhabditis elegans cdk-9 gene Proteins 0.000 abstract 1
- 101100029886 Caenorhabditis elegans lov-1 gene Proteins 0.000 abstract 1
- 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 abstract 1
- 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 abstract 1
- 108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 abstract 1
- 102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 abstract 1
- 101001059443 Homo sapiens Serine/threonine-protein kinase MARK1 Proteins 0.000 abstract 1
- 102100039313 Rho-associated protein kinase 1 Human genes 0.000 abstract 1
- 101710088411 Rho-associated protein kinase 1 Proteins 0.000 abstract 1
- 102100039314 Rho-associated protein kinase 2 Human genes 0.000 abstract 1
- 101710088493 Rho-associated protein kinase 2 Proteins 0.000 abstract 1
- 102100028921 Serine/threonine-protein kinase MARK1 Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cephalosporin Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91051907P | 2007-04-06 | 2007-04-06 | |
| EP08735845A EP2144909B1 (en) | 2007-04-06 | 2008-04-04 | [2,6]naphthyridines useful as protein kinase inhibitors |
| PCT/EP2008/054105 WO2008122615A1 (en) | 2007-04-06 | 2008-04-04 | [2, 6] naphthyridines useful as protein kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2144909T3 true PL2144909T3 (pl) | 2011-08-31 |
Family
ID=39590973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08735845T PL2144909T3 (pl) | 2007-04-06 | 2008-04-04 | [2,6]-Naftyrydyny użyteczne jako inhibitory kinaz białkowych |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20120142685A1 (pl) |
| EP (1) | EP2144909B1 (pl) |
| JP (1) | JP2010523530A (pl) |
| KR (1) | KR20100016291A (pl) |
| CN (1) | CN101679418A (pl) |
| AT (1) | ATE502940T1 (pl) |
| AU (1) | AU2008235456B2 (pl) |
| BR (1) | BRPI0810661A2 (pl) |
| CA (1) | CA2682340A1 (pl) |
| DE (1) | DE602008005729D1 (pl) |
| EA (1) | EA016108B1 (pl) |
| ES (1) | ES2363831T3 (pl) |
| MX (1) | MX2009010697A (pl) |
| PL (1) | PL2144909T3 (pl) |
| PT (1) | PT2144909E (pl) |
| WO (1) | WO2008122615A1 (pl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201100136A1 (ru) * | 2008-06-13 | 2011-08-30 | Новартис Аг | 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака |
| WO2011082268A2 (en) * | 2009-12-30 | 2011-07-07 | Arqule Inc. | Substituted naphthalenyl-pyrimidine compounds |
| EP2495244A1 (en) * | 2011-03-02 | 2012-09-05 | NovaSaid AB | Piperidinyl benzoimidazole derivatives as mPGEs-1 inhibitors |
| ES2761587T3 (es) | 2013-08-07 | 2020-05-20 | Friedrich Miescher Institute For Biomedical Res | Nuevo método de cribado para el tratamiento de la ataxia de Friedreich |
| PH12019500056B1 (en) | 2016-07-12 | 2024-01-31 | Revolution Medicines Inc | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| BR112019015075A2 (pt) | 2017-01-23 | 2020-03-10 | Revolution Medicines, Inc. | Compostos bicíclicos como inibidores de shp2 alostéricos |
| SG11201906412SA (en) | 2017-01-23 | 2019-08-27 | Revolution Medicines Inc | Pyridine compounds as allosteric shp2 inhibitors |
| JP7356414B2 (ja) | 2017-09-07 | 2023-10-04 | レヴォリューション・メディスンズ，インコーポレイテッド | がんを治療するためのｓｈｐ２阻害剤組成物および方法 |
| SG11202002941WA (en) | 2017-10-12 | 2020-04-29 | Revolution Medicines Inc | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
| CA3084058A1 (en) | 2017-12-15 | 2019-06-20 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric shp2 inhibitors |
| KR102890015B1 (ko) | 2020-06-30 | 2025-11-25 | 제넨테크, 인크. | 치환된 페닐 또는 피리디닐 모이어티를 갖는 serd 트리시클릭 화합물의 제조 방법 |
| AU2022284188A1 (en) * | 2021-06-04 | 2023-11-30 | Genentech, Inc. | 2, 8-diazaspiro [4.5] decane compounds |
| KR20240130693A (ko) * | 2021-12-16 | 2024-08-29 | 트랜스테라 사이언시즈 (난징), 인크. | Cdk9 억제제 및 이의 용도 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3928367A (en) * | 1969-04-14 | 1975-12-23 | Schering Corp | 1-Amino naphthyridines |
| US7550589B2 (en) * | 2004-09-21 | 2009-06-23 | Hoffman-La Roche Inc. | 6-(2-alkyl-phenyl)-pyrido[2,3-D]pyrimidines useful as protein kinase inhibitors |
| WO2008122614A1 (en) * | 2007-04-06 | 2008-10-16 | Novartis Ag | 2, 6-naphthyridine derivatives as protein kinase modulators |
-
2008
- 2008-04-04 CA CA002682340A patent/CA2682340A1/en not_active Abandoned
- 2008-04-04 EA EA200901325A patent/EA016108B1/ru not_active IP Right Cessation
- 2008-04-04 WO PCT/EP2008/054105 patent/WO2008122615A1/en not_active Ceased
- 2008-04-04 US US12/594,728 patent/US20120142685A1/en not_active Abandoned
- 2008-04-04 ES ES08735845T patent/ES2363831T3/es active Active
- 2008-04-04 PL PL08735845T patent/PL2144909T3/pl unknown
- 2008-04-04 AU AU2008235456A patent/AU2008235456B2/en not_active Expired - Fee Related
- 2008-04-04 AT AT08735845T patent/ATE502940T1/de active
- 2008-04-04 MX MX2009010697A patent/MX2009010697A/es active IP Right Grant
- 2008-04-04 DE DE602008005729T patent/DE602008005729D1/de active Active
- 2008-04-04 EP EP08735845A patent/EP2144909B1/en not_active Not-in-force
- 2008-04-04 BR BRPI0810661-4A patent/BRPI0810661A2/pt not_active IP Right Cessation
- 2008-04-04 JP JP2010501526A patent/JP2010523530A/ja active Pending
- 2008-04-04 PT PT08735845T patent/PT2144909E/pt unknown
- 2008-04-04 KR KR1020097023216A patent/KR20100016291A/ko not_active Withdrawn
- 2008-04-04 CN CN200880015131A patent/CN101679418A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010523530A (ja) | 2010-07-15 |
| WO2008122615A1 (en) | 2008-10-16 |
| DE602008005729D1 (en) | 2011-05-05 |
| EP2144909A1 (en) | 2010-01-20 |
| CN101679418A (zh) | 2010-03-24 |
| US20120142685A1 (en) | 2012-06-07 |
| ATE502940T1 (de) | 2011-04-15 |
| ES2363831T3 (es) | 2011-08-17 |
| BRPI0810661A2 (pt) | 2019-04-30 |
| PT2144909E (pt) | 2011-06-29 |
| EA200901325A1 (ru) | 2010-04-30 |
| AU2008235456A1 (en) | 2008-10-16 |
| AU2008235456B2 (en) | 2011-12-08 |
| MX2009010697A (es) | 2009-12-11 |
| EA016108B1 (ru) | 2012-02-28 |
| CA2682340A1 (en) | 2008-10-16 |
| EP2144909B1 (en) | 2011-03-23 |
| KR20100016291A (ko) | 2010-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2144909E (pt) | [2,6]naftiridinas úteis como inibidores de proteínas quinases | |
| BRPI0720525B8 (pt) | inibidores de mapk/erk quinase | |
| TW200740761A (en) | Histone deacetylase inhibitors | |
| WO2010009139A3 (en) | Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors | |
| TW200612913A (en) | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase | |
| EA200701257A1 (ru) | Пирролопиразолы в качестве сильнодействующих ингибиторов киназы | |
| WO2010009155A3 (en) | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases | |
| WO2010014930A3 (en) | Piperidine derivatives as jak3 inhibitors | |
| WO2008039359A3 (en) | Bicyclic pyrimidine kinase inhibitors | |
| MY148634A (en) | Pyridazinone derivatives | |
| MX2009004716A (es) | Compuestos y composiciones en la forma de inhibidores de quinasa de proteina. | |
| MY146989A (en) | Kinase inhibitors | |
| EA200970207A1 (ru) | Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов | |
| ATE479687T1 (de) | Kinaseinhibitoren | |
| MX2010009207A (es) | Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa. | |
| WO2006036395A3 (en) | Inhibitors of akt activity | |
| PL1981874T3 (pl) | Pochodne aminofenylowe jako nowe inhibitory deacetylazy histonowej | |
| MY148107A (en) | Kinase inhibitor | |
| WO2006122319A3 (en) | Histone deacetylase inhibitors | |
| MX2014014803A (es) | Derivados de imidazo[1,2-b]piridazina como inhibidores de cinasa. | |
| BRPI0809542A8 (pt) | Compostos derivados de indol tendo atividade de inibição de cpla2, composição farmacêutica, e métodos de produção dos referidos compostos | |
| GEP20166481B (en) | (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors | |
| WO2008054956A3 (en) | Kinase inhibitors | |
| EA200700143A1 (ru) | Производные замещенного пропенилпиперазина в качестве новых ингибиторов гистондеацетилазы | |
| WO2009129401A8 (en) | Kinase inhibitors |